DSGNHIGH SIGNALFINANCIAL10-K

DSGN shows significant financial deterioration with net losses widening 41% to $69.8M, R&D expenses surging 33%, and cash declining 25% to $16.9M amid expanded clinical development.

The company's burn rate has accelerated substantially with operating cash outflows increasing 26% to $54.4M annually, creating potential liquidity concerns given the declining cash position. While the expansion from two to three clinical programs explains higher R&D spending, the widening losses and cash consumption trajectory raises questions about runway and potential future financing needs.

Comparing 2026-03-09 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

DSGN's financials reflect an aggressive R&D expansion phase with expenses growing 33% to $59.1M while losses deepened 41% to $69.8M. Cash reserves declined 25% to $16.9M while current liabilities surged 54% to $13.1M, indicating accelerated cash burn and potential near-term financing pressures. The combination of widening losses, declining cash, and rising liabilities suggests the company may need to secure additional funding within the next 12-18 months to sustain operations.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+54.3%
$8.5M$13.1M

Current liabilities surged 54.3% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-43.2%
$340K$193K

Capex reduced 43.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
-40.7%
-$49.6M-$69.8M

Net income declined 40.7% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
+37.1%
$10.0M$13.7M

Liabilities grew 37.1% — significant increase in debt or obligations, assess impact on financial flexibility.

R&D Expense
P&L
+33.3%
$44.4M$59.1M

R&D investment increased 33.3% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-27.4%
-$62.4M-$79.5M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Operating Cash Flow
Cash Flow
-26.1%
-$43.1M-$54.4M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Cash & Equivalents
Balance Sheet
-25.3%
$22.6M$16.9M

Cash decreased 25.3% — monitor burn rate and upcoming capital needs.

Stockholders Equity
Balance Sheet
-12.2%
$242.1M$212.5M

Equity decreased 12.2% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
-10.3%
$252.1M$226.2M

Total assets contracted 10.3% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-10
ADDED
Unless the context otherwise indicates, references in this Annual Report to the terms Design , the Company , we , our , and us refer to Design Therapeutics, Inc.
We are early in our development efforts, with three product candidates in clinical development and with all of our other research programs currently in the nonclinical or discovery stage.
Early, interim, topline and preliminary data from our nonclinical studies or clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
International trade policies, including tariffs, sanctions and trade barriers, may adversely affect our business, financial condition, results of operations and growth prospects.
Disruptions to the operations of the FDA, the SEC, other U.S.
+7 more — sign up free →
REMOVED
Unless the context otherwise indicates, references in this Annual Report to the terms Design , the Company , we , our , and us refer to Design Therapeutics, Inc., and references to our common stock refers to our voting common stock.
We are early in our development efforts, and we have only two product candidates in clinical development, with all of our other research programs currently in the nonclinical or discovery stage.
In February 2022, the Investigational New Drug Application (IND) for our lead FA GeneTAC small molecule, DT-216, formulated as the prior DT-216 product candidate, was cleared by the U.S.
Food and Drug Administration (FDA) to commence Phase 1 clinical trials.
In December 2022, we reported positive initial data from the Phase 1 single-ascending dose (SAD) clinical trial and in August 2023, we reported data from the Phase 1 multiple-ascending dose (MAD) clinical trial of the prior DT-216 product candidate.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →